Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 18/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14496187 | 0.91 | CXCR3 (0.39) | CXCR3KCNH2PTGS1PTGS2 | |
| SCHEMBL13031390 | 0.87 | CXCR3 (0.39) | CXCR3KCNH2PTGS1PTGS2 | |
| SCHEMBL13031357 | 0.87 | CXCR3 (0.40) | CXCR3KCNH2 | |
| SCHEMBL13031134 | 0.86 | PTGS2 (0.35) | PTGS1PTGS2 | |
| SCHEMBL13031140 | 0.85 | PTGS2 (0.36) | KCNH2PTGS1PTGS2 | |
| SCHEMBL3576143 | 0.85 | CXCR3 (0.36) | CXCR3KCNH2 | |
| SCHEMBL13031262 | 0.84 | NPY5R (0.35) | KCNH2PTGS1PTGS2 | |
| SCHEMBL13031479 | 0.84 | NAMPT (0.36) | KCNH2PTGS1PTGS2 | |
| SCHEMBL13031155 | 0.84 | PTGS2 (0.33) | PTGS1PTGS2 | |
| SCHEMBL13031258 | 0.84 | GRIN2B (0.35) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885KCNH2 2030/4885PTGS1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.